IBD: Ulcerative Colitis
Biosimilars for IBD: Making the Transition Webinar
On May 28th, Dr. McCurdy answered the following questions in a very informative webinar presentation on Biosimilars:
- What’s the difference between a reference biologic drug and a biosimilar?
- Biosimilars: What’s Health Canada saying?
- What is the clinical evidence to date?
- How do doctors go about transitioning their patients from a reference biologic drug to a biosimilar?
Watch this webinar now!
Related Articles
Treating Crohn’s Disease Although several drugs are useful in controlling these conditions, as yet a cure has not been found. Since the disease is not curable, […]
It is estimated that 104,000 Canadians had ulcerative colitis in 2012, with 4,500 new cases annually. (Crohn’s and Colitis Foundation of Canada 2012) In 2008, physician […]
